Suven Pharmaceuticals enters into agreement with CSIR-IICT

11 Jun 2021 Evaluate

Suven Pharmaceuticals (SPL), CSIR-Indian Institute of Chemical Technology (CSIR-IICT), Hyderabad and CSIR-National Institute of Interdisciplinary Science & Technology, Thiruvananthapuram have entered into an agreement for the process technology transfer and manufacturing of the anti-COVID drug, Molnupiravir and 2-DG.

The agreements between the parties involve a total fee of Rs 8 lakh plus taxes for the grant of the licenses on non-exclusive basis to SPL. As per the agreement, CSIR IICT also would provide the process know how for the manufacture of new anti-COVID drug 2-DG to treat moderately and severely COVID infected patients to reduce their oxygen dependency.

Suven Pharmaceuticals is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.

Suven Pharma Share Price

1294.30 -0.05 (0.00%)
25-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.65
Dr. Reddys Lab 1209.00
Cipla 1503.40
Lupin 2107.30
Zydus Lifesciences 964.95
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.